Vinblastine Sulfate
Vinblastine Sulfate has anticancer activity, using FA-BSANPs as a drug carrier system could be effective in targeting Vinblastine Sulfate-sensitive tumors in the future. Vinblastine Sulfate could offer protection to the normal tissues against gamma-radiation-induced DNA strand breaks. The changes induced on the rabbit OM by Vinblastine sulphate are transient and that regenerative recovery leads to the restoration of the normal structure of the mucosa.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Antioxidants (Basel).2022, 11(12):2496.
Molecules.2020, 25(18):4283.
Molecules.2015, 20(11):20014-30
Biofactors.2018, 44(2):168-179
Nat Commun.2019, 10(1):5169
Int J Mol Sci.2020, 21(19):7209.
Biosci Rep.2020, 40(8):BSR20201219.
Neurochem Int.2023, 167:105537.
Lab Chip.2018, 18(6):971-978
Univerzita Karlova2022, 173245.
Related and Featured Products
Mutat Res. 2003 Apr 20;536(1-2):15-25.
Effect of vinblastine sulfate on gamma-radiation-induced DNA single-strand breaks in murine tissues.[Pubmed:
12694742]
The effect of Vinblastine Sulfate on gamma-radiation-induced DNA strand breaks in different tissues of tumour bearing mice, was studied by single-cell gel electrophoresis.
METHODS AND RESULTS:
Intraperitonial administration of different doses (0.25-2.0mg/kg body weight) of Vinblastine Sulfate 30 min prior to 4 Gy gamma-radiation exposure showed a dose-dependent decrease in the yield of DNA strand breaks in murine fibrosarcoma, blood leukocytes and bone marrow cells. The dose-dependent protection of cellular DNA against radiation-induced strand breaks as evidenced from comet tail length, tail moment and percent DNA in the tail, was more pronounced in bone marrow cells than in the cells of the tumor fibrosarcoma. In fibrosarcoma cells, the decrease in comet tail length, tail moment and percent DNA in the tail was detected at lower doses of Vinblastine Sulfate administration and these parameters were not significantly altered at higher doses, from that of the control irradiated.
CONCLUSIONS:
From this study, it appears that in addition to anticancer activity, Vinblastine Sulfate could offer protection to the normal tissues against gamma-radiation-induced DNA strand breaks.
Anat Histol Embryol. 2012 Oct;41(5):374-87.
Anticancer drug vinblastine sulphate induces transient morphological changes on the olfactory mucosa of the rabbit.[Pubmed:
22443492]
Vinblastine Sulfate (VBS) is an anticancer drug that acts by disrupting microtubule dynamics of highly mitotic tissue cells. The consequences of Vinblastine sulphate on the olfactory mucosa (OM), a tissue with high mitotic numbers, are not clearly understood.
METHODS AND RESULTS:
We used qualitative and quantitative methods to determine the structural changes that may be produced on the rabbit OM by Vinblastine sulphate. Following a single dose (0.31 mg/kg) of this drug, the structure of the mucosa was greatly altered on the first 3-5 days. The alteration was characterized by disarrangement of the normal layering of nuclei of the epithelia, degeneration of axonal bundles, occurrence of blood vessels within the bundles, localized death of cells of Bowman's glands and glandular degeneration. Surprisingly on or after day 7 and progressively to day 15 post-exposure, the OM was observed to regenerate and acquire normal morphology, and the vessels disappeared from the bundles. Relative to control values, bundle diameters, olfactory cell densities and cilia numbers decreased to as low as 53.1, 75.2 and 71.4%, respectively, on day 5. Volume density for the bundles, which was 28.6% in controls, decreased to a lowest value of 16.8% on day 5. In contrast, the volume density for the blood vessels was significantly lower in controls (19.9%) than in treated animals at day 2 (25.8%), day 3 (34.3%) and day 5 (31.5%).
CONCLUSIONS:
These findings suggest that the changes induced on the rabbit OM by Vinblastine sulphate are transient and that regenerative recovery leads to the restoration of the normal structure of the mucosa.
Can Med Assoc J. 1970 Feb 14;102(3):278-80.
A comparison of nitrogen mustard and vinblastine sulfate in the treatment of patients with Hodgkin's disease.[Pubmed:
5414540]
METHODS AND RESULTS:
In a crossover study the effectiveness of intermittent maintenance doses of nitrogen mustard was compared to that of Vinblastine Sulfate in the treatment of 61 patients with advanced Hodgkin's disease.
Forty-five of the patients had had previous radiation therapy. Nine of 29 patients who received nitrogen mustard as the first drug had a complete response and five had a partial response. The comparative results in 32 patients receiving Vinblastine Sulfate first were nine complete responses and 13 partial responses. The median duration of the complete responses to each drug was 43 weeks. The partial responses were of shorter duration. When the second drug was given in adequate doses, almost as many patients responded with a similar median duration of response.
CONCLUSIONS:
It is concluded that nitrogen mustard and Vinblastine Sulfate are equally effective single agents in the treatment of patients with advanced Hodgkin's disease and that patient preference would favour Vinblastine Sulfate because of its negligible side effects.
Int J Nanomedicine. 2009;4:321-33. Epub 2009 Dec 29.
Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM).[Pubmed:
20054435]
Response surface methodology (RSM) was used to optimize the process of preparing bovine serum albumin (BSA) nanoparticles by desolvation, then the resulting BSA nanoparticles (BSANPs) were conjugated with folate to produce a drug carrier system that can specifically target tumors.
METHODS AND RESULTS:
The anticancer drug, Vinblastine Sulfate (VBLS), was loaded to this tumor-specific drug carrier system for the purpose of overcoming the nonspecific targeting characteristics and side effects of the drug.
A central composite design was applied for modeling the process, which was composed of four independent variables, namely BSA concentration, the rate of adding ethanol (ethanol rate), ethanol amount, and the degree of crosslinking. The mean particle size and residual amino groups of the BSANPs were chosen as response variables. The interactive effects of the four independent variables on the response variables were studied. The characteristics of the nanoparticles; such as amount of folate conjugation, drug entrapment efficiency, drug-loading efficiency, surface morphology and release kinetics in vitro were investigated. Optimum conditions for preparing desired BSANPs, with a mean particle size of 156.6 nm and residual amino groups of 668.973 nM/mg, were obtained. The resulting folate-conjugated BSANPs (FA-BSANPs) showed a drug entrapment efficiency of 84.83% and drug-loading efficiency of 42.37%, respectively, and the amount of folate conjugation was 383.996 microM/g BSANPs.
CONCLUSIONS:
The results of this study indicate that using FA-BSANPs as a drug carrier system could be effective in targeting Vinblastine Sulfate-sensitive tumors in the future.
